Literature DB >> 12941891

Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B.

Sang-Moo Kang1, Qizhi Yao, Lizheng Guo, Richard W Compans.   

Abstract

To enhance the efficiency of antigen uptake at mucosal surfaces, CTB was conjugated to simian immunodeficiency virus (SIV) virus-like particles (VLPs). We characterized the immune responses to the Env and Gag proteins after intranasal administration. Intranasal immunization with a mixture of VLPs and CTB as an adjuvant elicited higher levels of SIV gp160-specific immunoglobulin G (IgG) in sera and IgA in mucosae, including saliva, vaginal-wash samples, lung, and intestine, as well as a higher level of neutralization activities than immunization with VLPs alone. Conjugation of CTB to VLPs also enhanced the SIV VLP-specific antibodies in sera and in mucosae to similar levels. Interestingly, CTB-conjugated VLPs showed higher levels of cytokine (gamma interferon)-producing splenocytes and cytotoxic-T-lymphocyte activities of immune cells than VLPs plus CTB, as well as an increased level of both IgG1 and IgG2a serum antibodies, which indicates enhancement of both Th1- and Th2-type cellular immune responses. These results demonstrate that CTB can be an effective mucosal adjuvant in the context of VLPs to induce enhanced humoral, as well as cellular, immune responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12941891      PMCID: PMC224576          DOI: 10.1128/jvi.77.18.9823-9830.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Formulation of HIV-envelope protein with lipid vesicles expressing ganglioside GM1 associated to cholera toxin B enhances mucosal immune responses.

Authors:  T Lian; T Bui; R J Ho
Journal:  Vaccine       Date:  1999-11-12       Impact factor: 3.641

2.  Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants.

Authors:  M J McCluskie; H L Davis
Journal:  Vaccine       Date:  2000-10-15       Impact factor: 3.641

3.  Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.

Authors:  A L Edinger; M Ahuja; T Sung; K C Baxter; B Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate.

Authors:  C Devito; J Hinkula; R Kaul; L Lopalco; J J Bwayo; F Plummer; M Clerici; K Broliden
Journal:  AIDS       Date:  2000-09-08       Impact factor: 4.177

5.  Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine.

Authors:  X Shen; T Lagergård; Y Yang; M Lindblad; M Fredriksson; J Holmgren
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

6.  Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain.

Authors:  L Deml; G Kratochwil; N Osterrieder; R Knüchel; H Wolf; R Wagner
Journal:  Virology       Date:  1997-08-18       Impact factor: 3.616

7.  Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques.

Authors:  X Paliard; Y Liu; R Wagner; H Wolf; J Baenziger; C M Walker
Journal:  AIDS Res Hum Retroviruses       Date:  2000-02-10       Impact factor: 2.205

8.  Identification of SIV env-specific CTL in the jejunal mucosa in vaginally exposed, seronegative rhesus macaques (Macaca mulatta).

Authors:  L A Wilson; M Murphey-Corb; L N Martin; R M Harrison; M S Ratterree; R P Bohm
Journal:  J Med Primatol       Date:  2000-08       Impact factor: 0.667

9.  Production and characterization of simian--human immunodeficiency virus-like particles.

Authors:  Q Yao; F M Kuhlmann; R Eller; R W Compans; C Chen
Journal:  AIDS Res Hum Retroviruses       Date:  2000-02-10       Impact factor: 2.205

10.  Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G).

Authors:  C B Morris; E Cheng; A Thanawastien; L Cárdenas-Freytag; J D Clements
Journal:  Vaccine       Date:  2000-03-17       Impact factor: 3.641

View more
  11 in total

1.  Human immunodeficiency virus-like particles activate multiple types of immune cells.

Authors:  Gangadhara Sailaja; Ioanna Skountzou; Fu-Shi Quan; Richard W Compans; Sang-Moo Kang
Journal:  Virology       Date:  2007-02-05       Impact factor: 3.616

Review 2.  Efficacy of AIDS vaccine strategies in nonhuman primates.

Authors:  Klaus Uberla
Journal:  Med Microbiol Immunol       Date:  2005-04-21       Impact factor: 3.402

3.  CXCR4-tropic, but not CCR5-tropic, human immunodeficiency virus infection is inhibited by the lipid raft-associated factors, acyclic retinoid analogs, and cholera toxin B subunit.

Authors:  Haruka Kamiyama; Katsura Kakoki; Sayuri Shigematsu; Mai Izumida; Yuka Yashima; Yuetsu Tanaka; Hideki Hayashi; Toshifumi Matsuyama; Hironori Sato; Naoki Yamamoto; Tetsuro Sano; Yoshihiro Shidoji; Yoshinao Kubo
Journal:  AIDS Res Hum Retroviruses       Date:  2012-08-27       Impact factor: 2.205

4.  Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection.

Authors:  Bao-Zhong Wang; Rui Xu; Fu-Shi Quan; Sang-Moo Kang; Li Wang; Richard W Compans
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

5.  Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses.

Authors:  Bao-Zhong Wang; Fu-Shi Quan; Sang-Moo Kang; Jadranka Bozja; Ioanna Skountzou; Richard W Compans
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

6.  Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant.

Authors:  Elena V Vassilieva; Bao-Zhong Wang; Andrei N Vzorov; Li Wang; Ying-Chun Wang; Jadranka Bozja; Rui Xu; Richard W Compans
Journal:  MBio       Date:  2011-02-15       Impact factor: 7.867

7.  Co-expression of ubiquitin gene and capsid protein gene enhances the potency of DNA immunization of PCV2 in mice.

Authors:  Fang Fu; Xuesong Li; Yuekun Lang; Yuju Yang; Guangzhi Tong; Guoxin Li; Yanjun Zhou; Xi Li
Journal:  Virol J       Date:  2011-05-30       Impact factor: 4.099

8.  A Novel Prime and Boost Regimen of HIV Virus-Like Particles with TLR4 Adjuvant MPLA Induces Th1 Oriented Immune Responses against HIV.

Authors:  Ethan Poteet; Phoebe Lewis; Feng Li; Sheng Zhang; Jianhua Gu; Changyi Chen; Sam On Ho; Thai Do; SuMing Chiang; Gary Fujii; Qizhi Yao
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

9.  Immunization with the recombinant Cholera toxin B fused to Fimbria 2 protein protects against Bordetella pertussis infection.

Authors:  Noelia Olivera; Celina E Castuma; Daniela Hozbor; María E Gaillard; Martín Rumbo; Ricardo M Gómez
Journal:  Biomed Res Int       Date:  2014-05-13       Impact factor: 3.411

Review 10.  Progression and Trends in Virus from Influenza A to COVID-19: An Overview of Recent Studies.

Authors:  Hakimeh Baghaei Daemi; Muhammad Fakhar-E-Alam Kulyar; Xinlin He; Chengfei Li; Morteza Karimpour; Xiaomei Sun; Zhong Zou; Meilin Jin
Journal:  Viruses       Date:  2021-06-15       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.